1、J.P.Morgan Healthcare ConferenceJanuary 2024Sage Therapeutics 2024Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements,which may be identified by the use of words such as“may,”“might,”“will,”“should,”“can,”“expect,”“plan,”“antici

2、pate,”“believe,”“estimate,”“project,”“intend,”“future,”“opportunity”,“goal”,“mission”,“potential,”“target”,or“continue,”and other similar expressions.Forward-looking statements in this presentation include statements regarding:plans,expectations and goals for commercialization of ZURZUVAE as a treat

3、ment for women with PPD,including our goal for ZURZUVAE to become first line therapy and standard of care in this indication and our reimbursement/access goals;our belief in the potential benefit and profile of ZURZUVAE in the treatment of PPD;the potential for success of our commercialization of ZU

4、RZUVAE for women with PPD;the potential for success of our other product candidates in various indications,including the potential profile and benefit of our other product candidates;our clinical development plans,including expected timelines for activities and our expectations as to potential resul

5、ts;our estimates as to the number of patients with disorders and diseases of interest to us and that we hope to help and the potential market for approved products and for our product candidates,if approved;the potential drivers of value in our business;the opportunity,mission,goals and vision for o

6、ur business;and our expectations with respect to maintaining a strong financial foundation.These forward-looking statements are neither promises nor guarantees of future performance,and are subject to a variety of risks and uncertainties,many of which are beyond our control,which could cause actual

7、results to differ materially from those contemplated in these forward-looking statements,including the risk that:We may not be successful in our commercialization efforts with respect to ZURZUVAE in the treatment of women with PPD;the market size and market acceptance for ZURZUVAE as a treatment for

8、 women with PPD may be significantly smaller than we expect;we may encounter reimbursement or market access related issues in the course of our commercialization activities;early positive signs may not be a signal of future success;ZURZUVAE may not achieve the clinical benefit in the treatment of wo

9、men with PPD that we expect;we may not generate revenue from sales of ZURZUVAE at the levels or on the timing we expect.Our clinical trials may not meet their primary endpoints or key secondary endpoints.Success in non-clinical studies or in prior clinical trials of our product candidates may not be

10、 repeated or observed in ongoing,planned or future studies involving the same compound or other product candidates.Non-clinical and clinical results from ongoing or future trials may not support further development of the product candidate,our planned regulatory pathway,or filing for or obtaining re

11、gulatory approval on the timelines we expect or at all and we may be required to conduct additional clinical trials or nonclinical studies which may not be successful.We may experience slower than expected enrollment in our clinical trials or may encounter other delays or problems,including in analy

12、zing data or requiring the need for additional analysis,data or patients,or due to timing and results of consultation with regulatory authorities,and such issues with any trial could cause delay in completion of the trial,availability of results and timing or success of future activities.We may enco

13、unter unexpected safety or tolerability issues with respect to any of our product candidates or marketed products;we may encounter different or more severe adverse events at higher doses,different frequency or length of dosing or in new indications.At any stage,regulatory authorities may ask for add

14、itional clinical trials,nonclinical studies or other data in order for us to proceed further in development or to file for or obtain regulatory approval.Other decisions or actions of the FDA or other regulatory authorities may affect the initiation,timing,design,size,progress and cost of clinical tr

15、ials or development efforts and our ability to proceed with further development.Even if our other product candidates are successfully developed and approved,the number of patients with the diseases or disorders our products treat or the subset of such patients we believe will use our products,the ne

16、ed for new treatment options,and the actual market for such products may be smaller than our current estimates.The anticipated benefits of our collaborations,including our collaboration with Biogen,may never be achieved.The need to align with our collaborators may hamper or delay our development and

17、 commercialization efforts or increase our costs;our business may be adversely affected and our costs may increase if any of our key collaborators fails to perform its obligations or terminates our collaboration.We may not be able to obtain and maintain adequate intellectual property protection or o

18、ther forms of data and marketing exclusivity for our products,or to defend our patent portfolio against challenges from third parties.We may face competition from others developing products or with approved products for similar uses as those for which our product candidates are being developed.Our o

19、perating expenses may be higher than forecasted and we may face unexpected expenses which could cause us to change our plans.Our revenues may be lower than we expect,including if we do not achieve market acceptance of ZURZUVAE in the treatment of women with PPD or if we do not achieve our access/rei

20、mbursement goals in this indication,or if our launch for other reasons is not as successful as we expect.We may not achieve expected milestones that trigger cash payments on the timing we expect,or at all.For these and other reasons,our expectations with respect to financial strength may not prove t

21、o be accurate.We may need or choose to raise additional funding,which may not be available on acceptable terms,or at all.We may not be able to establish and maintain key business relationships with third parties on acceptable terms or we may encounter problems with the performance of such third part

22、ies.We may encounter technical and other unexpected hurdles in the manufacture,development or commercialization of our products.Any of the foregoing or other factors may negatively impact our ability to achieve our goals,mission,opportunities,plans or expectations for our business.For additional dis

23、closure regarding these and other risks Sage faces,see the disclosure contained in the Risk Factors section of our most recent report,and in our other public filings,with the Securities and Exchange Commission,available on the SECs website at http:/www.sec.gov.Any forward-looking statement represent

24、 our views only as of today,and should not be relied upon as representing our views as of any subsequent date.We undertake no obligation to update or revise the information contained in this presentation,whether as a result of new information,future events or circumstances or otherwise.2OUR VISION:T

25、o fearlessly lead the way to create a world with better brain healthSage Therapeutics 2024Opportunity to become the leader in brain healthPatient inspired,patient led,patient firstZURZUVAEFirst and only oral product approved by the FDA specifically for postpartum depression(second approved product)D

26、ifferentiated pipeline driven by patient need,science,and external insightsScientific and therapeutic leadership within GABA and NMDA opportunities strong product engineStrong financial foundation to help create value for sustained growthValue-driven culture focused on doing whats right for patients

27、4Sage Therapeutics 2024COMPOUNDTARGET INDICATIONSPHASE 1PHASE 2PHASE 3STATUSPostpartum Depression FranchiseZURZUVAE*(zuranolone)CIVPostpartum DepressionZULRESSO(brexanolone)CIV injectionPostpartum DepressionNeuropsychiatry PipelineZuranolone*(SAGE-217)Major Depressive Disorder*Dalzanemdor(SAGE-718)H

28、untingtons Disease Cognitive DysfunctionParkinsons Disease Cognitive DysfunctionAlzheimers Disease Mild Cognitive Impairment and Mild DementiaSAGE-324*Essential TremorPrograms In EvaluationPlease refer to the U.S.Prescribing Information for ZULRESSO and the U.S.Prescribing Information for ZURZUVAESa

29、fety and efficacy for investigational uses or compounds have not been established.There is no guarantee that the outcome of these studies will be positive or result in approval by a Health Authority.*Collaboration Partners:Biogen Inc.and Shionogi for zuranolone and Biogen Inc.for SAGE-324*The FDA is

30、sued a CRL on August 4,2023,related to the NDA for the treatment of adults with MDD stating that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies will be needed.No Phase 3 tria

31、ls are currently ongoing.MARKETEDMARKETEDIN PHASE 3IN PHASE 2IN PHASE 2IN PHASE 2IN PHASE 25SAGE-689Acute GABA HypofunctionSAGE-421NMDA HypofunctionSAGE-319GABA HypofunctionSage Therapeutics 2024Multiple Expected Catalysts6Ongoing commercialization of ZURZUVAE in the treatment of women with postpart

32、um depression1.Advance dalzanemdor(SAGE-718)with 4 topline data readouts expected across HD,PD&AD2.Advance SAGE-324 with topline data expected in mid-20243.Progress earlier stage pipeline4.Sage Therapeutics 2024Multiple Expected Catalysts7Ongoing commercialization of ZURZUVAE in the treatment of wom

33、en with postpartum depression1.Advance dalzanemdor(SAGE-718)with 4 topline data readouts expected across HD,PD&AD2.Advance SAGE-324 with topline data expected in mid-20243.Progress earlier stage pipeline4.Sage Therapeutics 2024PPD poses a substantial burden to patients and their families;Significant

34、 unmet needs remain and require urgent treatment 8PPD symptoms are one of the most common complications of pregnancy and childbirth1Perinatal depression is inconsistently diagnosed and may be an undertreated condition1-4Mothers with perinatal depression often face significant challenges with functio

35、ning and infant-bonding5-9The economic burden associated with perinatal depression is vast and impacts patients,their families,employers,and health care payers10-12The COVID-19 Pandemic had a significant effect on perinatal mental health outcomes13-151.Bauman BL,Ko JY,Cox S,et al.MMWR MorbMortal Wkl

36、y Rep.2020;69(19):575-581 2.Ukatu N,et al.Psychosomatics.2018;59(3):211-219.3.Wang Z,et al.Transl Psychiatry.2021;11(1):543.4.Fonseca A,et al.J Affect Disord.2020;274:167-173.5.Beck CT,et al.Am J Nurs.2006;106(5):40-50.6.Wouk K,et al.Pediatrics.2016;137(1).7.Lilja G,et al.Scand J Caring Sci.2012;26(

37、2):245-253.8.Gaglardi L,et al.Arch Dis Child.2012;97(4):355-357.9.Kerstis B,et al.Arch Womens Ment Health.2016;19(1):87-94 10.Epperson CN et al.Curr Med Res&Opinion.2020;36(10):1707-1716 11.Moore-Simas TA et al.J Med Economics.2020;23(2):174-183.12.Luca DL et al.Math Pol Res.2019.13.Farewell CV,Jewe

38、ll J,Walls J,Leiferman JA.A mixed-methods pilot study of perinatal risk and resilience during COVID-19.J Prim Care Community Health.2020;11:24074.14.Liu CH EC,Mittal L.Risk factors for depression,anxiety,and PTSD symptoms in perinatal women during the COVID-19 pandemic.Psychiatry Res.2021

39、;295:113552.15.Gustafsson HC,Young AS,Doyle O,et al.Trajectories of perinatal depres sive symptoms in the context of the COVID-19 pandemic.Child Dev.Sep 2021;92(5):e749-e763.Sage Therapeutics 2024Widespread media attention and conversation is driving early demand“Zuranolones approval is yet another

40、reminder that when researchers broaden their lens to include womens health needs and in general,womens biology the benefits can be profound.”Lisa Jarvis,“New postpartum depression pill is a vital breakthrough”2 billion people viewed ZURZUVAE social media discussionsonline9Sage Therapeutics 202410Imp

41、ortant Safety InformationZURZUVAE may cause serious side effects,including decreased awareness and alertness,which can affect your ability to drive safely or safely do other dangerous activities.Do not drive,operate machinery,or do other dangerous activities until at least 12 hours after taking each

42、 dose.You may not be able to tell on your own if you can drive safely or tell how much ZURZUVAE is affecting you.ZURZUVAE may cause central nervous system(CNS)depressant effects including sleepiness,drowsiness,slow thinking,dizziness,confusion,and trouble walking.Taking alcohol,other medicines that

43、cause CNS depressant effects such as benzodiazepines,or opioids while taking ZURZUVAE can make these symptoms worse and may also cause trouble breathing.ZURZUVAE is a federally controlled substance schedule IV because it contains zuranolone,which can be abused or lead to dependence.Tell your healthc

44、are provider right away if you become pregnant or plan to become pregnant during treatment with ZURZUVAE.You should use effective birth control(contraception)during treatment with ZURZUVAE and for 1 week after the final dose.ZURZUVAE and other antidepressant medicines may increase the risk of suicid

45、al thoughts and actions in people 24 years of age and younger.ZURZUVAE is not for use in children.The most common side effects of ZURZUVAE include sleepiness or drowsiness,dizziness,common cold,diarrhea,feeling tired,weak,or having no energy,and urinary tract infection.Is Now AvailableZURZUVAE(50mg)

46、is approved for the treatment of postpartum depression in adults.A full course of ZURZUVAE includes 14 days of treatment.Note:image does not represent actual size of blister packPotential Rapid Improvement of PPD SymptomsIn the SKYLARK and ROBIN Studies,an improvement in depressive symptoms vs.place

47、bo was seen with a 14-day course treatment at day 15 beginning as early as day 3 and maintained at day 4514-day Short CourseIn the SKYLARK and ROBIN Studies,a statistically significantly greater improvement in depressive symptoms vs placebo was seen at day 15 following a 14-day short course treatmen

48、tFlexible ApproachIn clinical trials,ZURZUVAE was studied for use alone or as an adjunct to oral antidepressant therapy in the treatment of women with PPDNovel MOA&ClassZURZUVAE is neuroactive steroid GABAA receptor positive modulator with an MOA thought to be related to its positive allosteric modu

49、lation of GABAA receptorsGenerally Well-ToleratedThe most common adverse reactions(incidence 5%than placebo)are somnolence,dizziness,diarrhea,fatigue,nasopharyngitis,and urinary tract infection.See boxed warning for additional information.Sage Therapeutics 2024Focused on establishing ZURZUVAE as the

50、 first line therapy for women with PPD11Be First Choice:Establish ZURZUVAE as the first choice for women with PPDOptimize Access&Experience:Deliver broad and equitable access and enable a positive experience for all women with PPD prescribed ZURZUVAEDrive Urgency to Treat:Facilitate urgency to ident

51、ify signs and symptoms of PPD and enable proactive screening,diagnosis and treatmentBreak Stigma:Shift mindsets to legitimize PPD as a medical condition requiring urgent interventionZURZUVAE KEY LAUNCH GOALSSpecialtyDistributionModelJAMA and otherpublicationsACOG treatment guidelinesSage Therapeutic

52、s 2024Multiple Expected Catalysts12Katie Caregiver,Huntingtons DiseaseOngoing commercialization of ZURZUVAE in the treatment of women with postpartum depression1.Advance dalzanemdor(SAGE-718)with 4 topline data readouts expected across HD,PD&AD2.Advance SAGE-324 with topline data expected in mid-202

53、43.Progress earlier stage pipeline4.Sage Therapeutics 2024Globally,disorders involving cognitive impairment continue to increase in prevalence13188KHuntingtons Disease Global Prevalence1Cognitive Impairment in HD can occur up to 15 years before motor manifestation&is highly associated overall functi

54、onal decline8.8MParkinsons Disease Global Prevalence2Mild cognitive impairment(MCI)is diagnosed in nearly half of people with PD and is associated with poorer treatment outcomes,greater medical costs,and caregiver distress134MAlzheimers Disease Global Prevalence3Up to 50%of people with MCI due to AD

55、 progress to Alzheimers dementia within 5-10 years,which may impact a persons ability to remain independent4-7HD=Huntingtons disease,PD=Parkinsons disease,AD=Alzheimers disease 1.Pringsheim T,Wiltshire K,Day L,Dykeman J,Steeves T,Jette N.The incidence and prevalence of Huntingtons disease:a systemat

56、ic review and meta-analysis.Mov Disord.2012 Aug;27(9):1083-91.doi:10.1002/mds.25075.Epub 2012 Jun 12.PMID:22692795.2.Sage Therapeutics,Inc.Data on file.3.Sage Therapeutics,Inc.Data on file.4.Beglinger,Leigh J.,et al.Earliest functional declines in Huntington disease.Psychiatry research 178.2(2010):4

57、14-418.5.Jacobs,Milou,Ellen P.Hart,and Raymund AC Roos.Cognitive performance and apathy predict unemployment in Huntingtons disease mutation carriers.The Journal of Neuropsychiatry and Clinical Neurosciences 30.3(2018):188-193.6.Koerts,Janneke,et al.Working capacity of patients with Parkinsons disea

58、seA systematic review.Parkinsonism&related disorders 27(2016):9-24.7.Silvaggi,Fabiola,et al.Keeping people with dementia or mild cognitive impairment in employment:a literature review on its determinants.International journal of environmental research and public health 17.3(2020):842.Cognitive impai

59、rment has devastating impacts on patients,families,and societySage Therapeutics 2024141.Petrillo J.et.al.Patient Experiences in Early Huntingtons Disease.Poster presented at American Academy of Neurology Annual Meeting.Seattle,WA.April 2-7,2022 2.Sage Data on File;3.Petrillo J et.al.The Impact of Mi

60、ld Cognitive Impairment on Functioning in People With Parkinsons Disease.Poster presented at the International Parkinson and Movement Disorder Society,Copenhagen,Denmark.August 27-31,2023;AD:Alzheimers disease;PD:Parkinsons disease;HD:Huntingtons disease;MCI:Mild cognitive impairment;Cognitive impai

61、rment affects the ability to function every day and for many,the ability to stay independent“Theres zero multitasking in my life.And what it causes is extreme anxiety”Executive FunctionIndividuals in early stages of HD1“I wrote for websites and blogs,it used to take me maybe 20 or 30 minutes.And now

62、,it tends to take me a couple hours”“She started making a sandwich,then walked away,sat down and spaced out.She left the water on stove boiling.She forgets what she started”Memory&LearningCaregiver and Individual with AD-MCI2“Hell give me a task and Ill scratch my head.What was I supposed to do?Not

63、on drugs,not drinking,just a mental fog”Concentration&PlanningIndividuals with PD-MCI3“If I have a call where I have to focus,Im done.All the energy I had was focusing on this one call and trying to be an active participant.”“I can do only one thing at time.Otherwise I get stressed and it affects my

64、 speaking”Sage Therapeutics 2024Dalzanemdor(SAGE-718)has demonstrated consistent beneficial effects on cognitive performance in clinical studies to date15HV=healthy volunteers HV on Ketamine&Placebo n=19HV on Ketamine&SAGE-718 n=18n=6 n=16n=24Performance on Executive Functioning Tasks Across Dalzane

65、mdor StudiesZ-Transformed Change from Baseline to Last Assessment*(Mean change from baseline plotted)n=13n=17n=23n=25NO CHANGE0.20.40.60.81.01.2-0.2-0.4WORSENINGIMPROVEMENTHuntingtons DiseaseCLP-102BHealthy Volunteers w/Ketamine Challenge EXM-103 Parkinsons DiseasePARADIGM StudyAlzheimers DiseaseLUM

66、INARY StudyPlacebo-controlled Two Back Test Digital Symbol Substitution TestSpatial Working Memory TestSage Therapeutics 2024Alzheimers DiseaseParkinsons Disease16The dalzanemdor(SAGE-718)clinical development programPotential to reshape the treatment of patients with cognitive declineCLP-102-BOpen-l

67、abel study in HD,included as part of original HV MAD study,designed to evaluate safety,tolerability,PK and preliminary efficacy of SAGE-718 for HD cognitive impairment.CompletedDIMENSION(CIH-201)12-week RCT in patients with HD cognitive impairment,designed to evaluate efficacy(as measured by HD-CAB)

68、EnrollingPURVIEW(CIH-301)Long-term open-label safety study,enrolling participants from DIMENSION,SURVEYOR,and an additional de novo cohort.Designed to evaluate the long-term safety profile.EnrollingSURVEYOR(CIH-202)4-week RCT in patients with HD cognitive impairment.Designed to facilitate clinical m

69、eaningfulness evidence for DIMENSION.EnrollingHuntingtons DiseaseFDA Fast-track&Orphan Drug Designations;EMA Orphan Drug DesignationPARADIGM(CNP-201)Open-label study in PD-MCI designed to evaluate safety,tolerability,and preliminary efficacyCompletedPRECEDENT(CNP-202)Randomized,placebo-controlled tr

70、ial in PD-MCI designed to examine efficacy(WAIS-IV)Enrollment CompleteLUMINARY(CNA-201)Open-label study in AD-MCI and mild dementia designed to evaluate safety,tolerability,and preliminary efficacyLIGHTWAVE(CNA-202)Randomized,placebo-controlled trial in AD-MCI and mild dementia,designed to examine e

71、fficacy(WAIS-IV)EnrollingComplete“EXPAND&ACCELERATE”IndicationsSage Therapeutics 2024Data expected across all 3 indications over the course of 202417EARLY 2024(Q1/Q2)MID 2024(Q2/Q3)LATE 2024(Q3/Q4)Topline data from the PRECEDENT Study in PDTopline data from the SURVEYOR Study in HDTopline data from

72、the LIGHTWAVE Study in ADTopline data from the DIMENSION Study in HDSage Therapeutics 2024Multiple Expected Catalysts18Diann Patient/Advocate Essential TremorOngoing commercialization of ZURZUVAE in the treatment of women with postpartum depression1.Advance dalzanemdor(SAGE-718)with 4 topline data r

73、eadouts expected across HD,PD&AD2.Advance SAGE-324 with topline data expected in mid-20243.Progress earlier stage pipeline4.Sage Therapeutics 2024ET impacts individuals ability to perform a wide range of activities of daily living and their social-emotional well-beingIn an interview study of ET pati

74、ents and care partners with ET ranging from mild to very severe3:Gaps remain in bringing effective treatments to people suffering from Essential Tremor191.Furtado et al.Estimation of global age-specific prevalence of essential tremor by literature review of population-based studies.ICPE,2023.2.Saad

75、et al.Diagnosed and drug-treated prevalence of essential tremor in adult patients:retrospective analyses of two US healthcare claims databases.MDS 2022.3.Gerbasi et al.Patient experiences in essential tremor:Mapping functional impacts to existing measures using qualitative research.MDS 2023.An estim

76、ated 6.8M adults in the US have ET1,approximately 10-15%are diagnosed2I cant write.Thats the worst thing in the world I send my son to the bank for things.Its getting to the point where Im going to have to let him do all the financial work,because I just cant do it My mind is okay,but my body is fal

77、ling apart.100%had difficulty writing and pouring liquids80%had difficulty drinking,performing grooming and hygiene activities,dressing,eating,and holding reading material90%had at least one emotional impact of ETADL and social-emotional impacts were greater as severity of ET increasedSage Therapeut

78、ics 2024The SAGE-324 clinical development program20KINETIC Study(324-ETD-201)Phase 2,double-blind,placebo-controlled,randomized study evaluating the efficacy,safety,and tolerability of SAGE-324 in the treatment of individuals with essential tremor(as measured by TETRAS Performance Subscale Item 4 up

79、per limb tremor score)CompletedKINETIC2 Study(324-ETD-202)Phase 2,double-blind,randomized,placebo-controlled,doseresponse study of SAGE-324 for the treatment of essential tremor(as measured by TETRAS Performance Subscale Item 4 total score)Screening Closed324-ETD-303Open-label study of the longer-te

80、rm safety and tolerability of SAGE-324 in participants with Essential Tremor.Designed to evaluate the long-term safety profileEnrollingEssential TremorSage Therapeutics 2024Multiple Expected Catalysts21Ongoing commercialization of ZURZUVAE in the treatment of women with postpartum depression1.Advanc

81、e dalzanemdor(SAGE-718)with 4 topline data readouts expected across HD,PD&AD2.Advance SAGE-324 with topline data expected in mid-20243.Progress earlier stage pipeline4.Sage Therapeutics 2024Other potential areas of growth within the GABA and NMDA platforms22Profile of SAGE-319GABA Receptor PAMExtra-

82、synaptic GABAA receptor preferring positive allosteric modulatorProfile supporting daily,oral,chronic dosingDifferentiated clinical EEG signature compared to zuranolone and SAGE-324Potential indications:NEURODEVELOPMENTAL/MOTOR DISORDERSPreclinical profile of SAGE-421NMDA Receptor PAMNMDA receptor p

83、ositive allosteric modulatorProfile supporting daily,oral,chronic dosingPotential indications:COGNITIVE IMPAIRMENT,SCHIZOPHRENIASage Therapeutics 2024Potential Value Creating CatalystsPPD=postpartum depression,ET=essential tremor,HD=Huntingtons disease,PD=Parkinsons disease,AD=Alzheimers disease Neu

84、ropsychiatry Anticipated EventsZURZUVAE*Broader complement of commercial capabilitiesPresent additional analyses of data from NEST clinical program,including health economics and patient reported outcomesDalzanemdor(SAGE-718)Topline data from the PRECEDENT Study in PDTopline data from the SURVEYOR S

85、tudy in HDTopline data from the LIGHTWAVE Study in ADTopline data from the DIMENSION Study in HDPresent additional analyses of data from clinical development program as well as disease state and burden of disease research in HD,PD and/or ADSAGE-324*Topline data from Phase 2 KINETIC 2 Study in ETPres

86、ent additional analyses of data from clinical development program as well as disease state and burden of disease research in ETAdditional Expected MilestonesCash Balance1Maintain strong financial foundation*Collaboration Partners:Biogen Inc.and Shionogi for zuranolone and Biogen Inc.for SAGE-3241 In

87、 December we achieved the milestone from Biogen related to first commercial sale of ZURZUVAE for PPD.We expect to receive the$75M payment in the first quarter of 2024.232024202420242024EARLY 2024EARLY 2024MID 2024LATE 2024LATE 2024MID 2024OUR MISSON:Pioneer solutions to deliver life-changing brain health medicines,so every person can thrive